The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.
 
Arvind Dasari
Consulting or Advisory Role - Advanced Accelerator Applications; Hutchison MediPharma; Ipsen; Lexicon; Novartis; Voluntis
Research Funding - Eisai; Guardant Health; Hutchison MediPharma; Ipsen; Merck; Novartis
 
John S. Kauh
Employment - Glenmark; Hutchison MediPharma; Lilly
Stock and Other Ownership Interests - Hutchison MediPharma; Lilly
Travel, Accommodations, Expenses - Glenmark; Hutchison MediPharma; Lilly
 
Christopher Tucci
Employment - Hutchison MediPharma
 
Shivani Nanda
Employment - Hutchison MediPharma
Stock and Other Ownership Interests - Hutchison MediPharma
 
Marek K. Kania
Employment - Hutchison MediPharma
Leadership - Hutchison MediPharma
Stock and Other Ownership Interests - Hutchison MediPharma
 
Jennifer W Carlisle
No Relationships to Disclose
 
Andrew Scott Paulson
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Aptose Biosciences
Honoraria - Cardinal Health
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Bristol Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Pfizer
Research Funding - AstraZeneca (Inst); bristol myers squibb (Inst); Deciphera (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Hutchison MediPharma (Inst); incyte (Inst); Ipsen (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst)